[February 08, 2016] |
|
Kidney Cancer (Renal Cell Cancer) Pipeline Review, H2 2015 - Featuring 130+ Companies & Their Drug Profiles - Research and Markets
Research and Markets (http://www.researchandmarkets.com/research/kl6j7c/kidney_cancer)
has announced the addition of the "Kidney
Cancer (Renal Cell Cancer) - Pipeline Review, H2 2015" report
to their offering.
This report provides comprehensive information on the therapeutic
development for Kidney Cancer (Renal Cell Cancer), complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic
development for Kidney Cancer (Renal Cell Cancer) and special features
on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Key Topics Covered:
-
Introduction
-
Kidney Cancer (Renal Cell Cancer) Overview
-
Therapeutics Development
-
Pipeline Prducts for Kidney Cancer (Renal Cell Cancer) - Overview
-
Pipeline Products for Kidney Cancer (Renal Cell Cancer) - Comparative
Analysis
-
Kidney Cancer (Renal Cell Cancer) - Therapeutics under Development by
Companies
-
Kidney Cancer (Renal Cell Cancer) - Therapeutics under Investigation
by Universities/Institutes
-
Kidney Cancer (Renal Cell Cancer) - Pipeline Products Glance
-
Late Stage Products
-
Clinical Stage Products
-
Early Stage Products
-
Kidney Cancer (Renal Cell Cancer) - Products under Development by
Companies
-
Kidney Cancer (Renal Cell Cancer) - Products under Investigation by
Universities/Institutes
-
Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics
Development
Companies Mentioned
-
4SC AG
-
AbbVie Inc.
-
Acceleron Pharma, Inc.
-
Advanced Cancer Therapeutics
-
Advaxis, Inc.
-
Advenchen Laboratories, LLC
-
Alethia Biotherapeutics Inc.
-
Altor BioScience Corporation
-
Ambrx, Inc.
-
Amgen Inc.
-
Ampio Pharmaceuticals, Inc.
-
APEIRON Biologics AG
-
arGEN-X BV
-
Argos Therapeutics, Inc.
-
ArQule, Inc.
-
Arrowhead Research Corporation
-
Astellas Pharma Inc.
-
AstraZeneca Plc
-
ATLAB Pharma SAS (News - Alert)
-
Aurigene Discovery Technologies Limited
-
Bayer AG
-
Beta Pharma, Inc.
-
Beth Israel Deaconess Medical Center, Inc.
-
BIND Therapeutics, Inc.
-
Bio-Cancer Treatment International Limited
-
Bionomics Limited
-
Bionovis SA
-
Boehringer Ingelheim GmbH
-
Boston Biomedical, Inc.
-
Bristol-Myers Squibb Company
-
Caladrius Biosciences, Inc.
-
Calithera Biosciences, Inc.
-
CASI Pharmaceuticals Inc.
-
Celgene Corporation
-
Cellceutix Corporation
For more information visit http://www.researchandmarkets.com/research/kl6j7c/kidney_cancer
View source version on businesswire.com: http://www.businesswire.com/news/home/20160208005842/en/
[ Back To TMCnet.com's Homepage ]
|